- Home
- CELC vs NPFD Comparison
CELC vs NPFD Comparison
Compare CELC & NPFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- NPFD
- Stock Information
- Founded
- CELC 2011
- NPFD 2021
- Country
- CELC United States
- NPFD United States
- Employees
- CELC N/A
- NPFD N/A
- Industry
- CELC Medical Specialities
- NPFD Trusts Except Educational Religious and Charitable
- Sector
- CELC Health Care
- NPFD Finance
- Exchange
- CELC Nasdaq
- NPFD Nasdaq
- Market Cap
- CELC 489.7M
- NPFD 466.1M
- IPO Year
- CELC 2017
- NPFD N/A
- Fundamental
- Price
- CELC $12.86
- NPFD $18.95
- Analyst Decision
- CELC Strong Buy
- NPFD
- Analyst Count
- CELC 6
- NPFD 0
- Target Price
- CELC $29.17
- NPFD N/A
- AVG Volume (30 Days)
- CELC 232.9K
- NPFD 64.7K
- Earning Date
- CELC 11-14-2024
- NPFD 01-01-0001
- Dividend Yield
- CELC N/A
- NPFD 6.28%
- EPS Growth
- CELC N/A
- NPFD N/A
- EPS
- CELC N/A
- NPFD N/A
- Revenue
- CELC N/A
- NPFD N/A
- Revenue This Year
- CELC N/A
- NPFD N/A
- Revenue Next Year
- CELC N/A
- NPFD N/A
- P/E Ratio
- CELC N/A
- NPFD N/A
- Revenue Growth
- CELC N/A
- NPFD N/A
- 52 Week Low
- CELC $11.51
- NPFD $14.50
- 52 Week High
- CELC $22.19
- NPFD $18.07
- Technical
- Relative Strength Index (RSI)
- CELC 42.58
- NPFD 41.75
- Support Level
- CELC $11.94
- NPFD $19.11
- Resistance Level
- CELC $13.14
- NPFD $19.43
- Average True Range (ATR)
- CELC 0.51
- NPFD 0.15
- MACD
- CELC 0.07
- NPFD -0.04
- Stochastic Oscillator
- CELC 58.70
- NPFD 0.00
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About NPFD Nuveen Variable Rate Preferred & Income Fund
Nuveen Variable Rate Preferred&Income is a newly organized, diversified, closed-end management investment company. The Fund's investment objective is to seek to provide a high level of current income and total return.